On the evening of April 28, Shanghai Securities News, China Securities News, Heyuan Biotech released its first quarterly report for 2024. During the reporting period, the company achieved operating income of 5,957heroeshuntmegaways.41 million yuan, a year-on-year increase of 93.48%heroeshuntmegaways; The net profit loss attributable to the parent company was 42.1703 million yuan.
Specifically, during the reporting period, the company's cell gene therapy CRO business maintained steady growth, achieving revenue of 17.9618 million yuan, a year-on-year increase of 30.98%; the cell gene therapy CDMO business achieved revenue of 38.2132 million yuan, a year-on-year increase of 146.50%.
In addition, the company added more than 80 million yuan in new orders. With the further release of production capacity in the company's Lingang base, the continuous expansion of new technologies and processes, and the continuous expansion of new fields, Heyuan Biotech's CDMO business orders and revenue are expected to gradually recover. (He Xinyi)
